Cartesian Therapeutics Inc.
$ 6.85
16.89%
09 Jun - close price
- Market Cap 172,176,000 USD
- Current Price $ 6.85
- High / Low $ 9.33 / 6.59
- Stock P/E N/A
- Book Value -5.19
- EPS -5.80
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.16 %
- ROE -70.29 %
- 52 Week High 15.57
- 52 Week Low 5.60
About
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company is headquartered in Watertown, Massachusetts.
Analyst Target Price
$34.57
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-03-09 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-03-20 | 2024-11-07 | 2024-08-08 | 2024-05-08 | 2024-03-07 | 2023-11-13 | 2023-08-17 |
| Reported EPS | -0.95 | -2.7065 | -1.38 | -0.77 | -0.65 | -0.5935 | -0.42 | 0.64 | -0.8 | -0.07 | -0.06 | -0.07 |
| Estimated EPS | -0.7 | -0.79 | -0.84 | -0.65 | -0.71 | -0.8257 | -0.55 | -0.09 | -1.42 | -0.04 | -0.06 | -0.08 |
| Surprise | -0.25 | -1.9165 | -0.54 | -0.12 | 0.06 | 0.2322 | 0.13 | 0.73 | 0.62 | -0.03 | 0 | 0.01 |
| Surprise Percentage | -35.7143% | -242.5949% | -64.2857% | -18.4615% | 8.4507% | 28.1216% | 23.6364% | 811.1111% | 43.662% | -75% | 0% | 12.5% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.77 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RNAC
2026-06-09 18:09:31
BTIG has reiterated a "Buy" rating for Cartesian Therapeutics Inc (RNAC) with a price target of $44.00, indicating confidence despite the stock currently trading significantly lower. However, GuruFocus data suggests RNAC is highly overvalued, with a GF Value of $0.28 against a current price of $6.84, and a low GF Score of 29/100 due to weak financial strength, profitability, and growth. Investors are cautioned to consider both the analyst's bullish outlook and the significant valuation concerns.
2026-06-09 12:09:31
Cartesian Therapeutics (NASDAQ: RNAC) shares rose significantly after announcing a strategic licensing agreement with WestGene Biopharma. This partnership aims to develop in vivo chimeric antigen receptor T-cell therapies for autoimmune diseases using WestGene’s lipid nanoparticle platform and Cartesian’s mRNA payload. A Phase 1 study is expected to begin in the second half of 2026, with data anticipated in the first half of 2027.
2026-06-09 11:09:31
Cartesian Therapeutics has announced a strategic licensing agreement with Westgene Biopharma. This collaboration aims to accelerate the development of Cartesian's in vivo CAR-T platform. The primary focus of this initiative will be on treating autoimmune diseases.
2026-06-09 11:09:31
Cartesian Therapeutics announced a strategic licensing agreement with WestGene Biopharma to develop in vivo mRNA CAR-T therapies for autoimmune diseases, combining Cartesian’s Descartes-08 mRNA payload with WestGene’s targeted LNP platform. A Phase 1 trial in generalized myasthenia gravis is planned for the second half of 2026, with initial data expected in the first half of 2027. This collaboration aims to bypass traditional ex vivo CAR-T manufacturing, potentially accelerating the development of treatments for various autoimmune conditions.
2026-06-09 11:09:31
Cartesian Therapeutics has partnered with WestGene Biopharma in a strategic licensing agreement to advance in vivo CAR-T therapies for autoimmune diseases. This collaboration combines Cartesian's mRNA payloads with WestGene's targeted lipid nanoparticle (tLNP) platform, aiming for rapid clinical translation. A Phase 1 clinical trial is expected to start in the second half of 2026 for patients with myasthenia gravis, with initial clinical data anticipated in the first half of 2027.
2026-06-02 19:39:19
Morgan Stanley Smith Barney LLC has filed a Form 144 notice for proposed sales of Cartesian Therapeutics (RNAC) common stock. These sales are related to restricted stock vesting under a registered plan, with vesting dates identified as January 2, 2025, and January 2, 2026. The filing indicates the intent to sell, but does not detail actual transaction execution or cash flow.
